Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects - PubMed (original) (raw)

. 2015 Sep;138(Pt 9):2701-15.

doi: 10.1093/brain/awv199. Epub 2015 Jul 27.

Henrik Zetterberg 2, Argonde C van Harten 3, Lidia Glodzik 4, Pablo Martinez-Lage 5, Luisella Bocchio-Chiavetto 6, Lorena Rami 7, Oskar Hansson 8, Reisa Sperling 9, Sebastiaan Engelborghs 10, Ricardo S Osorio 4, Hugo Vanderstichele 11, Manu Vandijck 12, Harald Hampel 13, Stefan Teipl 14, Abhay Moghekar 15, Marilyn Albert 15, William T Hu 16, Jose A Monge Argilés 17, Ana Gorostidi 18, Charlotte E Teunissen 19, Peter P De Deyn 10, Bradley T Hyman 20, Jose L Molinuevo 7, Giovanni B Frisoni 21, Gurutz Linazasoro 5, Mony J de Leon 4, Wiesje M van der Flier 22, Philip Scheltens 3, Kaj Blennow 23, Leslie M Shaw 1, John Q Trojanowski 24; Alzheimer’s Disease Neuroimaging Initiative

Collaborators, Affiliations

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Jon B Toledo et al. Brain. 2015 Sep.

Abstract

In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex® measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-β1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-β amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-β1-42 and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE ε4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-β1-42 values and APOE ε2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1% at 44 years to 16% at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal fluid amyloid-β1-42 levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-β1-42, phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.

Keywords: Alzheimer’s disease; biomarkers; cognitive ageing; dementia; imaging.

© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

PubMed Disclaimer

Figures

None

In a large multicentre study, Toledo et al. examine core Alzheimer’s disease CSF biomarkers in 1233 cognitively normal subjects aged 40–85 years. Alzheimer disease-like changes in Aβ1-42 are seen as early as middle age, while APOE genotype strongly modifies age-related effects on both Aβ1–42 and phosphorylated/total tau.

Figure 1

Figure 1

CSF amyloid-β1-42, total tau and phosphorylated tau181 levels in association with ageing in healthy controls stratified by APOE genotype. Dashed lines represent the cut-off points for the biomarkers.

Figure 2

Figure 2

Estimated frequency of pathological amyloid-β (A) and neurodegeneration (N) categories according to age of the subjects. Plots represent all subjects and subjects stratified by gender and APOE genotype. Due to smaller sample size subjects with ε2 alleles were not stratified by gender. Shaded areas represent 95% CI.

Figure 3

Figure 3

Frequency of A+, N+, A+N− and A+N+ stratified by _APOE_-defined groups.

Figure 4

Figure 4

Differences in the frequency of the four biomarker groups in subjects with APOE ε3/ ε3 genotype compared subjects who are ε2 or ε4 allele carriers. The lines above the black dashed line indicate that the plotted group has a higher frequency of the studied biomarker category. For the gender plots values above the 0 represent a higher frequency for females, whereas values below 0 represent a higher frequency in males. Shaded areas represent 95% CI.

Similar articles

Cited by

References

    1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509–17. - PMC - PubMed
    1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795–804. - PMC - PubMed
    1. Berenguer RG, Monge Argiles JA, Ruiz CM, Paya JS, Blanco Canto MA, Santana CL. Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years. Alzheimer Dis Assoc Disord 2014; 28: 234–8. - PubMed
    1. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011; 121: 171–81. - PubMed
    1. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128: 755–66. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources